Related Experiment Video
Updated: Mar 14, 2026

Radiation Treatment of Organotypic Cultures from Submandibular and Parotid Salivary Glands Models Key In Vivo Characteristics
Published on: May 17, 2019
MDM2 and CDK4 amplifications are rare events in salivary duct carcinomas
Inga Grünewald1, Marcel Trautmann1, Alina Busch2
1Department of Pathology, University Hospital Muenster, Muenster, Germany.
Abstract:
Salivary duct carcinoma (SDC) is an aggressive adenocarcinoma of the salivary glands associated with poor clinical outcome. SDCs are known to carry TP53 mutations in about 50%, however, only little is known about alternative pathogenic mechanisms within the p53 regulatory network. Particularly, data on alterations of the oncogenes MDM2 and CDK4 located in the chromosomal region 12q13-15 are limited in SDC, while genomic rearrangements of the adjacent HMGA2 gene locus are well documented in subsets of SDCs. We here analyzed the mutational status of the TP53 gene, genomic amplification of MDM2, CDK4 and HMGA2 rearrangement/amplification as well as protein expression of TP53 (p53), MDM2 and CDK4 in 51 de novo and ex pleomorphic adenoma SDCs.25 of 51 cases were found to carry TP53 mutations, associated with extreme positive immunohistochemical p53 staining levels in 13 cases. Three out of 51 tumors had an MDM2 amplification, one of them coinciding with a CDK4 amplification and two with a HMGA2 rearrangement/amplification. Two of the MDM2 amplifications occurred in the setting of a TP53 mutation. Two out of 51 cases showed a CDK4 amplification, one synchronously being MDM2 amplified and the other one displaying concurrent low copy number increases of both, MDM2 and HMGA2.In summary, we here show that subgroups of SDCs display genomic amplifications of MDM2 and/or CDK4, partly in association with TP53 mutations and rearrangement/amplification of HMGA2. Further research is necessary to clarify the role of chromosomal region 12q13-15 alterations in SDC tumorigenesis and their potential prognostic and therapeutic relevance.
Insights
Salivary duct carcinoma (SDC) involves TP53 mutations and alterations in the p53 regulatory network. This study investigates MDM2, CDK4, and HMGA2 alterations in SDC, revealing new insights into tumorigenesis.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- Salivary duct carcinoma (SDC) is an aggressive cancer with poor outcomes.
- TP53 mutations are common in SDC, but other p53 regulatory network alterations are less understood.
- Alterations in MDM2, CDK4, and HMGA2 at chromosomal region 12q13-15 are implicated in SDC pathogenesis.
Purpose of the Study:
- To analyze TP53 mutations, MDM2/CDK4 amplifications, and HMGA2 rearrangements/amplifications in SDC.
- To assess the protein expression of p53, MDM2, and CDK4 in SDC.
- To investigate the role of 12q13-15 alterations in SDC tumorigenesis.
Main Methods:
- Analysis of TP53 mutational status.
- Genomic analysis for MDM2, CDK4 amplification, and HMGA2 rearrangement/amplification using techniques like FISH or array CGH.
- Immunohistochemistry for p53, MDM2, and CDK4 protein expression.
- Study included 51 SDC cases (de novo and ex pleomorphic adenoma).
Main Results:
- TP53 mutations were found in 25 out of 51 cases.
- MDM2 amplification occurred in 3 cases, CDK4 amplification in 2 cases.
- HMGA2 rearrangements/amplifications were observed in conjunction with MDM2/CDK4 alterations.
- Some MDM2/CDK4 amplifications were associated with TP53 mutations.
Conclusions:
- Subgroups of SDC exhibit genomic amplifications of MDM2 and/or CDK4.
- These amplifications can be associated with TP53 mutations and HMGA2 alterations.
- Further research is needed to understand the prognostic and therapeutic implications of 12q13-15 alterations in SDC.
Related Concept Videos
Abnormal Proliferation
M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...

